Making a Difference in Patients with Spinal Muscular Atrophy: Improving Diagnosis and Treatment

Spinal muscular atrophy (SMA) is an inherited condition that places a tremendous burden on patients, families, caregivers, and healthcare providers, with patients experiencing a wide range of complications and symptoms that are detrimental to day-to-day life. Although SMA management has historically consisted of supportive care, the therapeutic landscape has changed dramatically following the recent approval of transformative medications, particularly disease-modifying therapies (DMTs) that improve motor function and survival. In this educational activity, experts Dr Basil Darras and Dr Julie Parsons, seek to bring clinicians up-to-date by discussing recent advances in screening for SMA, as well as need-to-know information on newer DMTs, such as relevant clinical efficacy and safety data and recommendations for treatment selection.

Click here to access this educational activity:


Current Concepts in Diagnosing and Treating Alzheimer’s Disease

Are you confident diagnosing and treating patients with Alzheimer’s disease? This 30-minute video activity offers pearls to optimize care for patients with this challenging neurological disease. Join Dr Zoe Arvanitakis and Dr Marwan Sabbagh as these experts discuss the importance of an early and accurate diagnosis, review current agents and treatment strategies, and highlight emerging disease-modifying agents that could change the way Alzheimer’s disease is approached in the future. Expert insights from the 2021 AD/PD Conference are also addressed in this important educational activity.

Here is the link to the activity:

Best Practices for Disease Detection, Risk Stratification, and Treatment Selection in Osteoporosis

Are you confident implementing recent osteoporosis recommendations in your clinical practice? Despite clear guidance, screening rates remain suboptimal and many clinicians are hesitant to implement pharmacologic therapy. This 15-minute case-based CME activity, developed by osteoporosis experts Dr Rachel Pessah-Pollack and Dr Steven Petak, addresses screening, diagnosis, treatment strategies, and patient-specific treatment considerations for osteoporosis.

Accelerating New Standards of Oncology Care Amidst the Global Pandemic: Operational, Clinical, and Interpersonal Considerations – Gather-ed

The COVID-19 pandemic has significantly affected nearly every aspect of oncological practice because of the increased risk to patients with cancer and the impact on health care resources. This has led to rapid changes in when, where, and how to provide diagnostic procedures, treatment, and follow-up care. There is an urgent need to provide cancer care professionals with guidance, training, and support as they respond to unprecedented challenges in maintaining high-quality patient care.


This activity will be delivered via an innovative online platform and led by faculty experts in oncology using virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.

Here is the link to sign up with additional details. Once on the platform, please select a group to enroll in:

Tackling Challenging MS Case Scenarios: Evaluating Missed Opportunities to Improve Care

Multiple sclerosis (MS) is a chronic neurodegenerative disease with a complex clinical course, and many health care professionals may miss opportunities to deliver evidence-based care. Join our expert faculty as they discuss patient scenarios to highlight methods to avoid missed opportunities to provide optimal care for patients with MS.

Patient scenario one:  A Latina Woman With Relapsing-Remitting MS Planning to Have a Child
Click here to view this 15-minute activity:

Patient scenario two: An African American Male With Vision Problems and Motor Weakness
Click here to view this 15-minute  activity:


Faculty: Denise Bruen, ANP-BC, MSCN University of Virginia,  James Q. Miller Consultative MS Center, Charlottesville, VA.  Mariko Kita, MD, Chief of Medicine, Virginia Mason Medical Center, Director, Neurology Clinical Trials, Benaroya Research Institute, Seattle, WA

Getting Ahead of Migraine: Best Practices for Migraine Prevention – Migraine Diagnosis and Burden of Disease

My migraines made me feel like I was a part-time parent. They were so bad that my husband and I came to the difficult decision that we could not have more kids because I could not function as a parent ‒ I could barely function as an adult.” Do you know how migraine affects the daily lives of your patients? Join Dr Cynthia Armand and Dr Carrie Dougherty to learn more about caring for patients with this debilitating disease.

Cynthia E. Armand, MD, Assistant Professor of Neurology Albert Einstein College of Medicine, Fellowship Director Montefiore Headache Center, Bronx, NY

Carrie Dougherty, MD, FAHS, Associate Professor of Neurology Program Director, Headache Medicine Fellowship, Assistant Program Director, Neurology Residency MedStar Georgetown University Hospital, Washington, DC

Click here to view this activity:

Getting Ahead of Migraine: Best Practices for Migraine Prevention – Targeting CGRP for Migraine Prevention

Four anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies are approved for migraine prevention. To ensure clinicians are prepared to consider these agents when clinically indicated, this educational activity will compare the efficacy and safety of these therapies for migraine prevention and discuss strategies for shared decision-making.

Cynthia E. Armand, MD, Assistant Professor of Neurology Albert Einstein College of Medicine, Fellowship Director Montefiore Headache Center, Bronx, NY

Carrie Dougherty, MD, FAHS, Associate Professor of Neurology Program Director, Headache Medicine Fellowship, Assistant Program Director, Neurology Residency MedStar Georgetown University Hospital, Washington, DC

Click here to view this activity:

HER-Directed Therapies in Metastatic Breast Cancer: Safety and Efficacy Considerations

Despite advances in HER targeting, HER2-positive metastatic breast cancer typically progresses. Research has established that the HER2-HER3 complex is the true driver of HER2-amplified cancer and the effective inactivation of this complex is the new bar for novel therapies. In this interactive educational activity, Dr Hurvitz and Dr Tolaney share key data and expert perspectives on recently approved and emerging HER-targeted therapies for metastatic breast cancer.

Sara A. Hurvitz, MD, FACP, Professor of Medicine, Director, Breast Oncology Program, Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

Sara M. Tolaney, MD, MPH, Assistant Professor of Medicine, Harvard Medical School, Associate Director, Susan F. Smith Center for Women’s Cancers, Director, Clinical Trials, Breast Oncology, Director of Breast Immunotherapy Clinical Research Dana-Farber Cancer Institute, Boston, Massachusetts.

Click here to participate in this 30-minute CME activity:

Clinical Pearls for Advanced Practice Providers: Reversing Direct Oral Anticoagulants in the Emergency Department – ACEP Frontline Podcast

This online educational podcast offers clinical pearls for the assessment of bleeding severity in patients receiving DOACs; expert-guided insights to rapid reversal of urgent DOAC-associated bleeding; and practical strategies for aligning clinical practice with local hospital bleeding management protocols. Join Dr Colin Kaide and Eric Cucchi as they examine the latest recommendations for the management of life-threatening DOAC-associated bleeding.

Click here to enroll and listen to this 37-minute ACEP Frontline Podcast:


New Therapeutic Options in AML: An Update for Community Clinicians – Podcast

Have you heard about the latest clinical advances in AML therapy? Recent approvals and emerging therapies, such as epigenetic agents and newer cytotoxics, has transformed the care of patients with newly diagnosed and relapsed/refractory AML.

Join Dr Stephen A. Strickland and Dr Eunice S. Wang as they discuss recent science that provides guidance for the care team on the use of newly approved and novel strategies for AML management.

Click here to listen to this 45-minute CME podcast: